A Phase 2 interventional study of Melatonin tablet and Tranexamic Acid (TXA) in Melasma (Facial Melasma), sponsored by Hina Malik. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-09-11.
Sponsored by Hina Malik · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing Tranexamic Acid in Melanosis — 6 open to participants now, 7 under way, 2 of them phase 3. Tranexamic Acid · Melanosis.
Among the 16 studies testing Tranexamic Acid in Melanosis, this one is the 2nd largest by planned enrollment, is the only one that started in 2025, is the only one in phase 2, and was the 12th registered.
170 studies on the registry are indexed under Melanosis; 46 are open to participants now.
Browse Melanosis studies →6 of the 16 studies testing Tranexamic Acid in Melanosis are open now, in 3 countries. Recruiting first, the newest first:
Egymedicalpedia · Sites in Egypt
Ages 18–40
Dr.dr.Irma Bernadette, SpKK (K) · Sites in Indonesia
Ages 30–60 · Women only · Healthy volunteers
Sameh Sarsik · Sites in Egypt
Ages 18+ · Women only
Allied Hospital Faisalabad · Sites in Pakistan
Ages 18+
Assiut University
Ages 18–50 · Women only
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 19 Melanosis studies recruiting now, 8 (42%) set no upper age limit and 11 (58%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5 · Phase 4 3
First in 2016; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 40 across 157 interventional studies indexed under Melanosis.
Median enrollment 52 across the 16 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 16 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Hina Malik as lead sponsor.
Hina Malik has 1 study filed under Melanosis — fewer than ten, so there is no comparison to draw.
3 of the studies testing Tranexamic Acid in Melanosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07448415Phase 3Assiut UniversityEvaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma | 2027-02 |
| NCT07881328Allied Hospital FaisalabadBaseline Dermoscopic Vascular Score and Response to Oral Tranexamic Acid in Facial Melasma | 2027-06 |
| NCT07696806Sameh SarsikMicroneedling-Assisted Metformin, Tranexamic Acid, and Modified Kligman's Formula for Melasma | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing Tranexamic Acid in Melanosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare the efficacy of oral melatonin and oral tranexamic acid in treating melasma, with the aim of determining whether melatonin is more effective than tranexamic acid, as measured by MASI scores. Literature suggests melatonin may be more effective due to its antioxidant, anti-inflammatory, and anti-melanogenic properties. The findings will assess whether melatonin provides better efficacy and tolerance compared to tranexamic acid in managing this persistent condition. Efficacy will be assessed by comparing the baseline MASI scores with the scores obtained at six-week and twelve-week follow-up points based on the following cut-offs:
\<25% improvement Mild response 25-50% improvement Moderate Response 51-75% improvement Good response >75% improvement Excellent Response
This study will compare the efficacy of oral melatonin and oral tranexamic acid in treating melasma.Literature suggests melatonin may be more effective due to its antioxidant, anti-inflammatory, and anti-melanogenic properties.Efficacy will be assessed by comparing the baseline MASI scores with the scores obtained at six-week and twelve-week follow-up points based on the following cut-offs:
\<25% improvement Mild response 25-50% improvement Moderate Response 51-75% improvement Good response >75% improvement Excellent Response It's a Randomized Control Trial conducted at PAEC General Hospital. Study period is of 6 months.Total sample size is 180 patents.The sample is divided into two groups, with 80 patients assigned to each treatment.This study hypothesizes that oral melatonin will be more effective than oral tranexamic acid in reducing the severity of melasma, as measured by changes in the Melasma Area and Severity Index.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult patients aged 18-50 years diagnosed with melasma.
Patients with to melatonin, including pregnancy, breastfeeding, disorders, bleeding disorders, and diabetes, or contraindications to tranexamic acid, including thromboembolic events, history of thrombosis, renal impairment, and pregnancy or breastfeeding.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group A will receive oral melatonin 5mg daily at night for 3 months after ruling out any contraindications. Melasma Area and severity index will be calculated at day one , 6 weeks and 12 weeks.
Drug: Melatonin tablet
Group B will receive oral tranexamic acid 250mg twice daily for 3 months after ruling out any contraindications.Melasma area and severity index will than be calculated on day one , 6 weeks and 12 weeks.
Drug: Tranexamic Acid (TXA)
Group A will receive oral melatonin 5mg every night for 3 months
Group B will receive oral tranexamic acid 250mg twice daily for 3 months.
Total participants are 160, 80 in Group A and 80 in Group B
Group A will receive oral melatonin 5mg HS for 12 weeks and Group B will receive oral tranexamic acid 250 mg BD for 12 weeks and then the improvement will be assessed by calculating MASI score at day 1, 6weeks and 12 weeks.MASI score less than 10 is considered mild , 11-20 is considered moderate and more than 20 is considered Severe Melasma. An improvement greater than 25% in the MASI score will be considered as the threshold for treatment efficacy.
Time frame: 12 weeks
Efficacy of Oral Melatonin VS Oral Tranexamic Acid in the management of Melasma
As per literature Melatonin may be more effective due to its Antioxidant, Anti-inflammatory and anti-melanogenic properties. The findings will assess whether Melatonin provides better efficacy and tolerance compared to Tranexamic Acid in managing Melasma.An improvement greater than 25% in the MASI score will be considered as the threshold for treatment efficacy.
Time frame: 12 weeks
Plan to share: Yes — The plan to share de-identified individual participant data (IPD) from this clinical trial, including the efficacy of oral melatonin versus oral tranexamic acid in managing melasma, with researchers who submit a methodologically sound proposal for secondary analysis. The data shared will include the primary and secondary outcome measures, participant demographics, and other relevant study data. Data will be accessible 12 months after the primary publication of the trial results, via a secure online platform, with a data use agreement. Access will be granted to researchers who provide a detailed proposal and agree to the terms of data sharing, including maintaining participant confidentiality and not attempting to re-identify participants. Requests for data access should be directed to dr.hina567@gmail.com This IPD sharing plan aligns with the ICMJE's expectations for data sharing and transparency in clinical trials.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: January 2026 to janurary 2027
Access criteria: De-identified IPD will be shared with qualified researchers who submit a proposal for secondary analysis that aligns with the trial's objectives and methodology. Proposals must outline planned analyses, including statistical methods, and will be reviewed by an independent committee for scientific merit and feasibility. A data sharing agreement must be signed, ensuring participant confidentiality and data protection. Requests can be sent to dr.hina567@gmail.com. Access will be granted for analyses that advance knowledge in melasma management, such as exploring treatment efficacy, safety, or predictors of response.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2025, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Melatonin · Tranexamic Acid